The community owned platform rewards people for sharing the data they already own, contributing to health research and discoveries that save lives.
As the health and DNA data platform grows, it will become increasingly valuable to the entire health research industry.
As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data.
There is currently little incentive for consumers to contribute their health and DNA data to a third party database.
There are also multiple privacy, security, and trust issues that limit broad participation.
Luna DNA founded and manages a community owned data platform that rewards individuals shares in the platform for contributing their DNA data and other medical information. Shares entitle members to a share in the proceeds from health research and discoveries. The proceeds flow back to the community as dividends as researchers pay to access the data for discovery.
The Luna DNA team combines a deep background in medicine, DNA sequencing, big data, and large scale Internet communities.
CEO & Co-Founder
Bob Kain is a renowned pioneer in genomics. At Illumina, Bob led the invention of the modern, high throughput genome sequencer that brought the cost from millions of dollars down to less than $1000.
He joined Illumina pre-IPO in 1999 and retired in 2014, as the Chief Engineering Officer. Bob is lead inventor on 28 U.S. patents that led to the breakthroughs that have revolutionized genome sequencing. Prior to joining Illumina, Bob was the Director of the Microarray Business Unit at Molecular Dynamics. He is also on the Scientific Advisory Boards of Dovetail Genomics, Singular Genomics, and Edenroc Biosecurity, and is the co-founder of Revere Biosensor. Additionally, he is the co-founder and chairman of the board of a successful health & fitness business, Mesa Rim Climbing and Fitness Center, with multiple locations in San Diego and Reno, Nevada.
Bob received a BS in Physics from San Diego State University and an MBA from Saint Mary’s College of California.
President & Co-Founder
Dawn served as the Vice President of Applied Genomics at Illumina, Inc. Dawn integrated market development strategies with product and business model innovation to accelerate the application of genomics in medicine and personal healthcare. Dawn joined Illumina in 2005.
Prior to Illumina, Dawn spent seven years at Genaissance Pharmaceuticals, one of the first genomics startups focused on individualized medicine and DNA-based diagnostic testing.
She holds a BS in biology from the University of Vermont and a MBA from the University of Connecticut School of Business.
Scott Kahn, Ph.D
Chief Information Officer, Former CIO and VP of Commercial and Enterprise Informatics at Illumina
CFO & Co-Founder, Chief Investment Officer & Co-Founder at Ganley Investments, Former Citigroup Executive
Vice President, Strategy & Business Operations, Former Director, Market Strategy and Innovation, Clinical Genomics at Illumina
Head of Dev Ops & Automation, Former Sr. DevOps Architect, Clinical Genomics at Illumina
Co-Founder, CTO & Co-Founder of Redemption Games, Blockchain Developer and Y Combinator Alumni
Carlos Bustamante, Ph.D
Advisor, Professor of Biomedical Data Science and Genetics at Stanford University
Aristides A.N. Patrinos, Ph.D
Advisor, Former President Synthetic Genomics, Lead at Human Genome Project
Advisor, Founder & CEO of Reneo Capital healthcare fund; former VP Amylin Pharmaceuticals
Luna DNA is backed by leading healthcare and technology investors including:
Biotech VC Fund
Arch Venture Partners
Biotech VC Fund
Future-Tech VC Fund
UK Tech VC Fund
CEO of Prelude Capital
Co-Founder of Illumina
Luna DNA Raises $4 Million Including Key Investors Illumina Ventures and Arch Venture Partners
Funding supports company's mission to launch a health discovery platform and engage a global community of data contributors